In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form of epilepsy, scientists have developed a new gene replacement therapy in ...
Novartis NVS obtained approval from the European Commission (EC) for Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal ...
A gene therapy designed to replace the missing protein that causes fragile X syndrome restored several disease-relevant ...
Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...
(RTTNews) - Novartis AG (NVS), Wednesday, announced the positive results from its Phase III clinical program of investigational gene replacement therapy, intrathecal onasemnogene abeparvovec or OAV101 ...
Researchers at Cincinnati Children's have demonstrated that AAV-mediated delivery of the human FMR1 gene can restore FMRP ...
Novartis NVS obtained FDA approval for onasemnogene abeparvovec-brve, a gene replacement therapy, for children two years and older, teens, and adults with spinal muscular atrophy (SMA). The therapy ...
Theresa is the lead Morning Rounds writer, and her stories focus on gender-affirming care, reproductive health, and mental health. You can reach Theresa on Signal at theresagaff.97. Get your daily ...
This sponsored article was provided by a partner and is not editorial content from Los Angeles Magazine or the Engine Vision Media Network. Every cell in your body holds a unique genetic code within ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results